Biotech Vico Therapeutics raises $31 million (27 million) in Series A financing round to advance therapies for rare central nervous system diseases
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease
Other early discovery stage RNA editing platform focuses on RETT syndrome
Funding led by LSP, co-led by Kurma Partners, supported b... Biopharmaceuticals, Neurology, Venture Capital Vico Therapeutics, RNA modulating therapies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Ataxia | Biotechnology | Brain | Funding | Huntington's Disease | Neurology | Pharmaceuticals | Rett Syndrome | Venture Capital